Forte Biosciences (FBRX) Retained Earnings (2016 - 2026)
Forte Biosciences' (FBRX) quarterly Retained Earnings came in at -$245.5 million in Q1 2026, down 44.71% year-on-year from -$444.0 million in Q1 2025, and down 9.91% on a QoQ basis from -$223.4 million in Q4 2025.
Forte Biosciences (FBRX) Retained Earnings (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Retained Earnings data on file, last reported at -$245.5 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 44.71% year-over-year to -$245.5 million in Q1 2026; TTM through Mar 2026 was -$245.5 million, a 44.71% decrease from a year earlier, with the FY2025 full-year figure at -$223.4 million, down 45.05% from the prior year.
- Retained Earnings for Q1 2026 stood at -$245.5 million, down from -$223.4 million in the prior quarter.
- Over the last five years, Retained Earnings for FBRX reached as high as -$6000.0 in Q3 2025 and fell as low as -$245.5 million in Q1 2026.
- Historically, Retained Earnings has averaged -$117.5 million across 5 years, with a median of -$112.6 million in 2023.
- On a YoY basis, Retained Earnings climbed as much as 100.0% in 2025 and fell as far as 2584228.57% in 2025.
- Year by year, Retained Earnings stood at -$87.0 million in 2022, then plunged by 36.16% to -$118.5 million in 2023, then declined by 29.93% to -$154.0 million in 2024, then plunged by 45.05% to -$223.4 million in 2025, then slipped by 9.91% to -$245.5 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$245.5 million in Q1 2026, -$223.4 million in Q4 2025, and -$6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | -245.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -245.50 Mn |
| Dec 31, 2025 | -223.37 Mn |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -180.90 Mn |
| Mar 31, 2025 | -169.65 Mn |
| Dec 31, 2024 | -154.00 Mn |
| Sep 30, 2024 | -146.80 Mn |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | -125.94 Mn |
| Dec 31, 2023 | -118.52 Mn |
| Sep 30, 2023 | -112.65 Mn |
| Jun 30, 2023 | -102.69 Mn |
| Mar 31, 2023 | -93.80 Mn |
| Dec 31, 2022 | -87.04 Mn |
| Sep 30, 2022 | -82.20 Mn |
| Jun 30, 2022 | -78.77 Mn |
| Mar 31, 2022 | -75.70 Mn |
| Dec 31, 2021 | -73.17 Mn |
| Sep 30, 2021 | -69.80 Mn |
| Jun 30, 2021 | -62.07 Mn |